Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience

In English

Författare

  • Joachim Burman
  • Ellen Iacobaeus
  • Anders Svenningsson
  • Jan Lycke
  • Martin Gunnarsson
  • Petra Nilsson
  • Magnus Vrethem
  • Sten Fredrikson
  • Claes Martin
  • Anna Sandstedt
  • Bertil Uggla
  • Stig Lenhoff
  • Jan-Erik Johansson
  • Cecilia Isaksson
  • Hans Hagglund
  • Kristina Carlson
  • Jan Fagius
Visa allt

Summary, in English

Background Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS. Methods Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months. Results At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%). Conclusions HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.

Publiceringsår

2014

Språk

Engelska

Sidor

1116-1121

Publikation/Tidskrift/Serie

Journal of Neurology, Neurosurgery and Psychiatry

Volym

85

Issue

10

Dokumenttyp

Artikel i tidskrift

Förlag

BMJ Publishing Group

Ämne

  • Neurology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1468-330X